In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Shaping The Medical Industry, April 2014

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February through March 2014.

You may also be interested in...



PMA Major Deficiency Letters Seem To Be Creeping Back Up. Here’s What FDA Wants You To Know

The latest medical device user fee (MDUFA) reports seem to indicate the percentage of premarket applications that receive a major deficiency letter are starting to come back up. US FDA says a key reason for the letters is because of insufficient testing information from device sponsors. The agency offers some steps that sponsors can take to avoid getting one of the dreaded missives.

Guidance: FDA Won’t Ask For Notice On Some Device Mods Tied To COVID-19

Sponsors of PMA or HDE-authorized devices can make some modifications in response to COVID-19 without first alerting the US FDA under a recent guidance document.

Altaire Recalled Millions Of OTC Eye Drops, Halted Production After Repeat GMP Problems Found

“Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate,” FDA says. Warning submitted in March said falsifying data was found in making batch release decisions related to whether certain sterile ophthalmic drugs contained viable microorganisms.

Topics

Related Companies

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel